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Edited by Hans-Dieter KlenkAbstract Upon receptor-mediated activation, the gp41 hydro-
phobic, conserved fusion peptide inserts into the target mem-
brane and promotes the kind of perturbations required for the
progression of the HIV-cell fusion reaction. Using a synthetic
combinatorial library we have identiﬁed all D-amino acid hexa-
peptide sequences that inhibited the fusion peptide capacity of
perturbing model membranes. Two hexapeptides that eﬀectively
inhibited the fusion peptide in these systems were subsequently
shown to inhibit cell–cell fusion promoted by gp41 expressed at
cell surfaces. These observations might be of importance for
understanding the mechanisms underlying fusion peptide activity
and suggest new strategies for screening compounds that target
these viral sequences.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The human immunodeﬁciency virus-1 (HIV-1) relies on the
fusogenic activity of the gp120/41 glycoprotein at the surface
of the virion to enter and infect its CD4+ host cells [1]. When
expressed at the surface of cells infected by HIV-1, this enve-
lope protein may also induce cell–cell fusion and syncytia for-
mation [2]. Induction of syncitia is a phenotype associated to
the predominant T-tropic virus isolated from symptomatic
individuals [3]. This process may contribute to the depletion
of cells supporting viral replication and be related to the pro-
gression of the disease in humans [4]. Consequently, HIV-1
envelope glycoproteins constitute an important focus for the
development of antiviral therapies [5–7].
Mutational analysis conﬁrms the involvement of the con-
served gp41 N-terminal hydrophobic fusion peptide (FP) seg-Abbreviations: ANTS, 8-aminonaphtalene-1,3,6-trisulfonic acid
sodium salt; DMSO, dimethylsulfoxide; DPX, p-xylenebis(pyridi-
nium)bromide; FP, fusion peptide; LUVs, large unilamellar vesicles;
POPG, 1-palmitoyl-2-oleoylphosphatidylglycerol; PS, positional scan-
ning; SCL, synthetic combinatorial library
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Comprehensive structure–function investigations of the com-
plete glycoprotein have been restricted due to the diﬃculties
of expressing gp41 constructs including this region. Conse-
quently, HIV FP action mechanism analyses have been cir-
cumscribed to the study of representative synthetic sequences
(reviewed in: [13]). Membrane interactions of these synthetic
FP derivatives were ﬁrst studied at a molecular level by Rafal-
ski et al. [14] and extensively characterized afterwards by other
groups (reviewed in: [15,16]; see also: [17–21]). The fact that li-
pid-bilayer destabilization is speciﬁcally promoted by func-
tional, but not defective mutant FP analogs indicates that: (i)
the activity of synthetic derivatives measured in model mem-
branes is physiologically relevant; and (ii) FP sequence bears
an intrinsic capacity to perturb membranes, i.e., it does not
function as an inert integral anchor.
Given its high degree of residue conservation among the dif-
ferent HIV-1 clades and isolates [8], FP action might in princi-
ple constitute a suitable target for therapeutic intervention
[8,22–25]. In the present study, we have utilized a biophysical
assay: FP-induced liposome permeabilization, as a surrogate
of FP activity for screening a synthetic peptide combinatorial
library (SCL) [26,27]. We have developed an assay in which
each peptide mixture making up an SCL can be tested for its
ability to inhibit FP lytic activity on large unilamellar vesicles
(LUVs). Several individual hexapeptides were identiﬁed that
were found to inhibit FP activity in these model systems. Nota-
bly, two of these sequences were also inhibitory in gp41-in-
duced cell–cell fusion assays. Our ﬁndings provide further
support to the relevance of FP activity measured in model
membrane systems, and also validate its use as a functional as-
say for SCL screening.2. Materials and methods
2.1. Materials
NH2-AVGIGALFLGFLGAAGSTMGARS-CONH2 (FP) was syn-
thesized and puriﬁed (estimated homogeneity >90%) at the Proteomics
Unit of the University Pompeu-Fabra (Barcelona, Spain). Peptide
stock solutions were prepared in dimethylsulfoxide (DMSO) (spectros-
copy grade). AVGIGA hexapeptide was from Bachem (Bubendorf,
Switzerland) and T-20 was a gift of Roche Palo Alto (Palo Alto,
CA, USA). N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)phosphatidylethanol-
amine (N-NBD-PE), N-(lissamine rhodamine B sulfonyl)phosphatidyl-
ethanolamine (N-Rh-PE), 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC), and 1-palmitoyl-2-oleoyl-phosphatidylglycerol (POPG) wereblished by Elsevier B.V. All rights reserved.
Fig. 1. (A) Leakage of vesicular contents (ANTS/DPX assay) induced
by the HIV-1 FP in POPG vesicles. Increasing doses of peptide were
incubated with POPG LUV (50 lM phospholipid) for 1 h at 37 C.
Extent of leakage (means of two independent measurements) was
subsequently plotted as a function of the lipid-to-peptide mole ratio.
(B) Eﬀects on FP-induced leakage of all D-amino acid hexapeptide
mixtures derived from a sub-library with ﬁxed positions 2. The FP
concentration was 1 lM and extents of leakage were measured at the
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Aminonaphthalene-1,3,6-trisulfonic acid sodium salt (ANTS) and p-
xylenebis(pyridinium)bromide (DPX) were from Molecular Probes
(Junction City, OR, USA). Triton X-100 was obtained from Sigma
(St. Louis, MO, USA). All other reagents were of analytical grade.
2.2. Synthesis of peptide libraries and individual hexapeptides
The peptide library and individual hexapeptides were synthesized by
solid-phase methods and simultaneous multiple peptide synthesis using
N-(9-ﬂuorenyl) methoxy-carbonyl (Fmoc) chemistry [28]. Peptides
were assembled on polystyrene aminomethyl-RAM resin to yield pep-
tide as C-terminal amide using diisopropylcarbodiimide/hydrox-
ibenzotriazol-mediated couplings. The all-D-amino acid hexapeptide
SCL was synthesized in the so-called positional scanning (PS) format
described previously [29]. The mixture (‘‘X’’) positions were incorpo-
rated by coupling a mixture of 19 D-amino acids (cysteine was omitted
to avoid the formation of uncontrolled intermolecular disulphide
bridges), with the relative ratios adjusted to yield near equimolar incor-
poration. After synthetic procedures [30] the peptide mixtures were sol-
ubilized in 5% DMSO/H2O, to a ﬁnal concentration of 3 mg/ml, and
stored at 20 C.
Individual peptides were synthesized using the corresponding D-ami-
no acids and puriﬁed by preparative reversed phase (RP) high-pressure
liquid chromatography (HPLC) with a Waters Delta Pak C18 column.
HPLC and MALDI-TOF (matrix-assisted laser desorption/ionization
time-of-ﬂight) mass spectrometry were used to characterize the puriﬁed
peptide.
2.3. Vesicle preparation and permeability assay
LUVs were prepared following the extrusion method of Hope et al.
[31] in 5 mM HEPES, 100 mM NaCl (pH 7.4) buﬀer. Lipid concentra-
tions of liposome suspensions were determined by phosphate analysis.
Mean diameter of vesicles in suspension, 95 nm, was estimated by
quasielastic light scattering using a Malvern Zeta-Sizer instrument.
Release of vesicular contents to the medium was monitored by the
ANTS/DPX assay [32]. LUV containing 12.5 mM ANTS, 45 mM
DPX, 20 mM NaCl and 5 mM HEPES were obtained by separating
the unencapsulatedmaterial by gel ﬁltration in a SephadexG-75 column
eluted with 5 mM HEPES, 100 mM NaCl (pH 7.4). Osmolarities were
adjusted to 200 mosm in a cryoscopic osmometer (Osmomat 030,
Gonotec, Berlin, Germany). ANTS ﬂuorescence measurements were
conducted in a Perkin–Elmer LS50-B spectroﬂuorimeter. ANTS emis-
sion was set at 520 nm and the excitation at 355 nm. A cutoﬀ ﬁlter
(470 nm) was placed between the sample and the emission monochro-
mator. 0% leakage corresponded to the ﬂuorescence of the vesicles at
time zero, in the absence of peptide; 100% leakage was the ﬂuorescence
value obtained after addition of TritonX-100 (0.5% v/v). For the screen-
ing of the SCL, the FP concentration was ﬁxed at 1 lM and extents of
leakage were measured at the FP-to-lipid mole ratio of 1:50. Each hex-
apeptide mixture was incubated for 30 min in DMSO with the FP (FP-
to-hexapeptide mole ratio was 1:100) prior to addition to the vesicles.
2.4. Cell–cell fusion assay
Syncytium formation assays were carried out using CHO-Env cells
(NIH AIDS Research and Reference Reagent Program, contributed
by C. Weiss and J. White). CHO-WT expressing HIV-1 HXB2 Env
were grown and assayed according to contributors’ instructions.
CHO-WT cells (eﬀector cells) were co-seeded with HeLaT4+ cells (tar-
get cells) expressing CD4 and CXCR4 (ARRRP-NIH, contributed by
R. Axel) and incubated overnight. Syncytia were subsequently scored
under phase contrast or after ﬁxing and staining, using an Olympus
CKX41 inverted microscope equipped with a Camedia C-5050 digital
camera (Olympus-Europe, Hamburg, Germany). Syncityum inhibition
assay was performed incubating peptides in the culture medium for
60 min with eﬀector CHO-WT cells prior to co-culturing with target
HeLaT4+ cells.FP-to-lipid mole ratio of 1:50. Each mixture was incubated for 30 min
in DMSO with the FP (FP-to-hexapeptide mole ratio was 1:100) prior
to addition to the vesicles. No eﬀect, stimulation and inhibition are
illustrated by D-Ala, D-Phe, and D-Gln, respectively. CTL corresponds
to the value in the absence of hexapeptides but with the same amount
of DMSO. The sub-libraries alone did not induce any leakage. The
bars represent means of four independent measurements plus standard
deviations. Conditions otherwise as in the previous panel.3. Results
FP sequence is absolutely required for gp41 fusogenic activ-
ity [10–12]. Previous studies have demonstrated that viral FP-induced pore-formation in liposomes is sensitive to physiolog-
ically relevant factors such as single blocking mutations [33–
36]. In fact, pore-formation activity of functional FPs occurs
well below the membrane rupture tensions caused by simple
transfer of mass to the bilayers (insertion), indicating that this
phenomenon reﬂects an intrinsic property of these viral se-
quences [13,37]. Thus, we have used pore-formation in model
vesicles as a functional assay to carry out the isolation of all
D-amino acid hexapeptides potentially inhibitory of FP activ-
ity (Fig. 1).
Fig. 1A illustrates the ability of the gp41 FP 23-mer analog
to permeabilize POPG LUV. This is a well-documented phe-
nomenon that reﬂects the assembly of permeating pores in
the vesicles [14,16,34,38,39]. A peptide dose that approxi-
mately induced half of the total leakage (i.e., 1:50 peptide-to-
lipid mole ratio) was selected for the hexapeptide SCL screen-
ing (Fig. 1B). The PS-SCL consisted of six sub-libraries; in
each sub-library, a single position of the hexapeptide was de-
ﬁned with each one of 19 D-amino acids (i.e., 19 peptide mix-
tures/sub-library, each one corresponding to one of the natural
amino acids except cysteine), while the remaining positions
were composed of mixtures of all D-amino acids except cys-
teine. Each sub-library was pre-mixed with FP in DMSO prior
to addition to the POPG LUV suspension. As an example, pa-
nel B in Fig. 1 displays the eﬀects of representative mixtures in
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duced leakage.
Thus, the library used in our study (Fig. 2) was made up of
114 peptide mixtures and is represented as: Ac-o1xxxxx-NH2,
Ac-xo2xxxx-NH2, Ac-xxo3xxx-NH2, Ac-xxxo4xx-NH2, Ac-
xxxxo5x-NH2, and Ac-xxxxxo6-NH2 (o: deﬁned by one of 19
D-amino acids; x: near equimolar mixture of 19 D-amino
acids). Each of the 114 peptide mixtures contained approxi-
mately 2.5 · 106 (195) diﬀerent peptides. Each sub-library ad-
dressed a separate position of the hexapeptide and, when
used in concert, the data provided information about the most
important amino acid residue at each position. Such segrega-Fig. 2. (A) Screening of Ac-o1xxxxx-NH2, Ac-xo2xxxx-NH2, Ac-xxo3xxx-
inhibition of FP permeabilizing activity. Each peptide mixture was screened at
described in the previous ﬁgure. Each panel represents a set of 19 peptide mix
represent percentages of leakage increase (i.e., negative increase reﬂects in
Inhibition of FP-induced POPG LUV permeabilization by all D-amino acid
were acetylated at N-terminus and amidated at C-terminus. In these assays thetion permits information to be obtained in a single assay,
which is then used to synthesize series of individual peptides di-
rectly from the screening results.
Fig. 2A shows the eﬀects of the complete SCL on FP-induced
POPG LUV permeability. The increase or decrease in leakage
over that observed in absence of the hexapeptide mixtures (0 le-
vel) was plotted for each deﬁned position. For most positions
the intrinsic lytic eﬀect of the sub-library alone was null or neg-
ligible, but in certain instances (indicated by the stars) the value
of the sub-library-induced leakage oscillated between 10% and
15%. Thus, leakage induced by the sub-library alone was
subtracted from the observed leakage when required. ClearNH2, Ac-xxxo4xx-NH2, Ac-xxxxo5x-NH2, and Ac-xxxxxo6-NH2 for
FP-to-hexapeptide 1:100 mole ratio under the experimental conditions
tures having a common residue at a deﬁned position (X axis). The bars
hibition). Means of four independent measurements are plotted. (B)
hexapeptides derived from the previous SCL screening. The sequences
FP concentration was 1 lMand the FP-to-hexapeptide mole ratio 1:40.
Fig. 3. Peptide inhibition of gp41-induced cell–cell fusion. (A) Eﬀect of
all D-amino acid hexapeptides on syncytium formation (hexapeptide
concentration: 5 lM). Bars represent the number of nuclei present in
syncytial plaques (fused cells containing 4 or more nuclei) per ﬁeld.
Values correspond to means of four independent experiments plus
standard deviations. Depicted sequences were acetylated at N-terminus
and amidated at C-terminus. (B) Inhibition of gp41 fusion activity by
incubation with peptides. Target-eﬀector cells grown in 96-well plates
were treated with T-20 (20 nM), Ac-gqidev-NH2 (50 lM) or AVGIGA
(1 mM). CTL corresponds to untreated control. (C) Quantitation of
inhibition by pre-incubation in solution with T-20 (squares and solid
lines), Ac-gqidev-NH2 (circles and dashed lines), Ac-gqidqv-NH2
(triangles and dotted line) and AVGIGA (diamonds and dot-dashed
line). Means of four independent measurements plus standard devia-
tions are displayed. Lines correspond to best ﬁts to hyperbolic functions.
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mixtures, suggesting that inhibition or promotion were due to
individual peptide(s) present in the mixture. The so-called
deconvolution process of the library consisted, ﬁrst, in selecting
the most active mixtures as inhibitors, and identifying the rele-
vant amino acid residues for each position. The greatest diﬀer-
ences in the inhibitory eﬀect (values below 0 level) between the
most active mixtures and the others were observed within posi-
tions 2 and 5. Since target vesicles were made of anionic phos-
pholipids, as an additional criterion, Asp and Glu eﬀects were
neglected when these residues exerted at the same position com-
parable inhibition (e.g., at positions 1, 2, 3 or 6).
As a result of our focused deconvolution process, we selected
the following mixtures at each position: g(1)-p/q/s(2)-i(3)-d(4)-
e/q(5)-v(6). The six possible D-amino acid hexapeptide se-
quences with putative anti-FP activity were synthesized and
subsequently assayed against FP (Fig. 2B). Three sequences re-
sulted clearly inhibitory (i.e., they induced >50% reduction in
observed leakage): Ac-gqidev-NH2, Ac-gqidqv-NH2 and Ac-
gsidqv-NH2. These sequences were further selected as potential
inhibitors of gp41 activity to be tested in gp41-induced cell–cell
fusion assays (Fig. 3).
In accordance with their capacity to inhibit gp41 activity,
Ac-gqidev-NH2 and Ac-gqidqv-NH2 signiﬁcantly reduced syn-
cytium formation at a concentration of 5 lM (Fig. 3A). The
Ac-gsidqv-NH2 hexapeptide, which also inhibited FP-induced
pore formation in liposomes, did not appreciably suppress
gp41 activity under these conditions. Finally, a negative con-
trol sequence, Ac-gpidqv-NH2, which did not aﬀect FP activity
in model membranes (Fig. 2B), was not inhibitory in the cell–
cell fusion assays either. All D-amino acid hexapeptides tested
in these assays inhibited cell growth only when used at ·103
higher concentrations (not shown). Thus, cell–cell fusion re-
sults appear to be consistent with speciﬁc gp41 inhibition in-
duced by Ac-gqid(e/q)v-NH2 sequences.
The inhibitory potency of the isolated Ac-gqidev-NH2 and
Ac-gqidqv-NH2 hexapeptides was subsequently compared
with those of the speciﬁc inhibitors T-20 and all L-amino acid
AVGIGA hexapeptide (panels B and C). The former has been
shown to inhibit gp41-induced fusion in the nM range [40,41],
while the latter is inhibitory in the mM range [22]. Co-incuba-
tion of the eﬀector and target cells at 37 C in the absence of
peptides resulted in formation of large syncytia (control in pa-
nel B). When T-20 (20 nM), Ac-gqidev-NH2 (50 lM) or AV-
GIGA (1 mM) were present in the external solution, they
inhibited fusion as evidenced by the large decrease in multinu-
cleated cells in the culture (Fig. 3B). These compounds inhib-
ited fusion in a dose-dependent manner showing apparent
IC50 values of ca. 4 nM, 20 lM and 150 lM, respectively
(Fig. 3C). Thus, when compared with isolated Ac-gqidev-
NH2 hexapeptide, T-20 showed a ca. 5000· inhibitory potency
(or 500–1000·, when considered the diﬀerences in molecular
weight). In contrast, AVGIGA hexapeptide required higher
doses than Ac-gqidev-NH2 to suppress fusion. The sequence
Ac-gqidqv-NH2 (apparent IC50 value of ca. 100 lM) was also
less eﬀective than Ac-gqidev-NH2, but still more inhibitory
than AVGIGA. Neither of the peptides showed a lytic activity
on the cells within the concentration range tested here. Thus,
the isolated D-amino acid sequences seem to represent opti-
mized versions of the previously described inhibitory hexapep-
tides [22].4. Discussion
The growth in worldwide AIDS epidemic together with the
emergence and spread of drug-resistant HIV variants reinforces
the need of implementing new therapies with unprecedented
mechanisms of action [5–7]. Rescue therapies based on the fu-
sion inhibitor T-20 (enfuvirtide, fuzeon) have been recently
proven useful in the treatment of multidrug-resistant virus in-
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that the repertoire of potential anti-HIV fusion-inhibitors
might be improved with the addition of agents showing ability
to interfere with conserved gp41 FP activity [8,22–25]. Owens
and coworkers [22] demonstrated the capacity of AVGIGA
hexapeptide, identical in amino acid sequence to the gp41 N-
terminus, to completely inhibit syncitium formation mediated
by HIV-1 envelope glycoproteins expressed at the surface of
HeLa CD4+ cells, an observation that has been reproduced in
the present work (Fig. 3). The inhibitory eﬀect was sequence-
speciﬁc and dose-dependent. These authors suggested that the
inhibitors might interact with its homologous FP sequence at
gp41 thereby preventing its normal fusogenic function. This
suggestion was supported by later studies in model membranes
by Pereira et al. [42], which revealed that N-terminal AVGIGA
hexapeptide also interfered with FP-vesicle interaction.
Based on those ﬁndings, we decided to make use of the mem-
brane-permeabilizing FP activity for screening an all D-amino
acid hexapeptide PS-SCL (Figs. 1 and 2). The inhibitory Ac-
gqidev-NH2 and Ac-gqidqv-NH2 hexapeptides identiﬁed using
the liposome-based screening also inhibited gp41-induced fu-
sion in a dose-dependent manner (Fig. 3). Both sequences
showed an increased potency in comparison to AVGIGA
(Fig. 3). A substitution of polar D-Gln by hydrophobic D-
Pro in position 2 rendered a sequence inactive against FP
(Fig. 2) or gp41 (Fig. 3). Moreover, Ac-gqidev-NH sequence
inhibited cell–cell fusion more potently than less polar Ac-
gqidqv-NH2 (Fig. 3). Thus, the inhibitory eﬀect of these com-
pounds seemed to be sequence-speciﬁc, and not merely based
on hydrophobic interactions with either FP or membranes.
HIV-envelope-mediated membrane fusion is a multi-step
process that oﬀers several targets for intervention. According
to Blumenthal and coworkers [43], it is presumed that the
FP inserts into the target membrane upon engagement of the
co-receptor by the envelope, a process that is preceded by at
least three distinct steps: CD4 receptor engagement, pre-hair-
pin formation and co-recepror–receptor co-localization. The
fact that anti-gp41 hexapeptides blocked FP-induced LUV
permeabilization suggests that these compounds interfere with
FP fusogenic function. Thus, we surmise that hexapeptides
interact with target FP along the fusion pathway at the stages
that precede insertion and alter its capacity to interact with
membranes. In line with this prediction, we have observed that
the hexapeptides that were inhibitory for leakage and gp41-in-
duced cell–cell fusion, enhanced peptide-induced cation-as-
sisted vesicle fusion (not shown). This is consistent with our
previous work indicating that leakage and fusion are conﬂict-
ing processes sustained by diﬀerent peptide structures
[16,38,39]. Thus, our results indicate that the inhibition mech-
anism might be based on the capacity of inhibitory hexapep-
tides to promote the extended FP conformations that reduce
leakage and stimulate vesicle fusion. Structural analyses are
under way to sustain that hypothesis.
Therefore, the inhibitory heaxapeptides and T-20 are postu-
lated to inhibit gp41-mediated fusion according to diﬀerent
mechanisms [5–7,22,40,41]. Supporting this view, when Ac-gqi-
dev-NH2 or Ac-gqidqv-NH2 was mixed with T-20 a slightly
negative synergy was observed in fusion inhibition assays (not
shown). Thus, we anticipate that optimized versions of the fu-
sion-inhibitors described here might be used in combination
with, and/or as an alternative to T-20 in order to reduce the
probability of resistant virus emergence during rescue therapies.5. Concluding remarks
The use of a biophysical assay that included isolated syn-
thetic FP derivatives and model membranes has been proven
useful in the screening and identiﬁcation of compounds with
speciﬁc anti-gp41 activity. This novel approach obviates po-
tential unspeciﬁc side eﬀects that SCLs might cause on com-
plex cellular systems during the screening procedure.
Consequently, a similar methodology could be applied to the
identiﬁcation of compounds active against various viral fusion
domains, such as inﬂuenza hemagglutinin or Ebola-GP2 FP
sequences, whose abilities to form permeating pores in model
membranes have been shown to be sensitive to mutations that
block glycoprotein fusogenic activity [33,35–37]. Finally, we
caution that the approach described here might serves to estab-
lish potential inhibitory compounds, which might turn not
being the most active sequences. However, these compounds
might comprise useful leads for rational optimization once
the inhibition mechanism is ﬁrmly established.
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